Technology/ Title

Hedgehog inhibitor as an anti-cancer agent

Technology Type

Biotechnology

Device/Diagnostics

Pharmaceutical

Others:_____________-

Contact Person

Name: Karena Juan

Title: Project Manager

Telephone(work): +886-02-7700-3800  ext. 5234

Mobile:

Email: ytjuan@dcb.org.tw

Link

http://

 

 

Technology Description

 

Summary of Invention:

1.      Hedgehog inhibitor screening technology platforms

2.      Highly potent hedgehog inhibitors that overcome drug resistant issue have been identified. (the vismodegib-resistant Smo-D473H mutant has inhibition activity IC50 less than 50 nM).

3.      Compound is highly efficacious in vivo animal model. Compound shows ~90% tumor growth inhibition in 40 mpk and significant dose response. In the cholangiocarcinoma TFK-1 Xenograft Models, the tumor growth inhibition rate (1-T/C) can reach 56.7% or more.

 

Advantages when compared to the existing technologies:

Develop inhibitors that bind to the marketed drug vismodegib with different Smoothened protein binding sites, improve drug resistance. Develop drugs that inhibit both tumor cells and cancer stem cells, and treat special patients with solid tumors, so they are highly competitive and market value.

Intellectual Property

PCT and Taiwan patent had been filed

Key Publications

 

Business Opportunity

Anti-cancer therapy for basal cell carcinoma and cholangiocarcinoma

 

 

 

▌技術簡介(現況)

開發與目前上市藥物vismodegib具不同Smoothened蛋白質結合位置的抑制劑,改善藥物的抗藥性,開發能同時抑制腫瘤細胞與腫瘤幹細胞的藥物,針對實質固態瘤之特殊病患治療,因此極富競爭力與市場價值。

 

▌技術規格

具專利性Hedgehog抑制劑抗癌藥物

 

▌技術特色

1.Hedgehog抑制劑抗癌藥物篩選技術平台

2.已開發之hedgehog抑制劑抗藥性的化合物(對vismodegib抗藥性Smo-D473H突變抑制活性IC50值小於50 nM)。

3.目前in vitro活性最佳化合物,於Ptch +/- Medulloblastoma Allografts in vivo Animal Model ,其腫瘤生長抑制率 (1-T/C) 可達90 %以上。於Cholangiocarcinoma (Bile duct carcinoma, 膽道癌) in vivo Xenograft Models,其腫瘤生長抑制率 (1-T/C)可達56.7%。

 

▌應用範圍

癌症治療

 

▌接受技術者具備基礎建議(設備)

具備新藥臨床開發經驗或承接能力者

 

▌接受技術者具備基礎建議(專業)

抗體臨床前開發技能。

 

▌技術分類

藥品開發

 

▌專利狀態

已申請PCT及中華民國專利


聯絡人廖宜亭

TEL02-7700-3800 # 5297

E-mailjessieliao@dcb.org.tw

 

最後更新日期:2019.03.27